![]() Under the agreement, Voyager provided Sangamo with access to a TRACER capsid to be combined with Sangamo’s zinc finger transcriptional regulators (ZF-TRs) designed to treat prion disease. announced a definitive license agreement for a potential treatment of prion disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |